Eric Lawitz, MD
Gastroenterology · San Antonio, TXNPI 1578661716
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.7%. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $1376.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$169K
- Novo Nordisk$151K
- Intercept Pharmaceuticals, Inc.$87K
- AbbVie$81K
- Boehringer Ingelheim International GmbH$63K
- Boehringer Ingelheim$35K
- plus $191K from 22 others
Across 3,832 payments — averaging $15,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$10.8M
- Boehringer Ingelheim$6.7M
- Astrazeneca UK Limited$5.1M
- Eli Lilly$3.3M
- Novartis$3.1M
- Boehringer Ingelheim International GmbH$3.1M
- plus $26.6M from 51 others
What the payments were for
- Consulting fees$295,49538%
- Speaking & faculty fees$390,42450%
- Travel & lodging$79,40810%
- Food & beverage$10,9521%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 181 | $168,558 |
| Novo Nordisk | 66 | $150,677 |
| Intercept Pharmaceuticals, Inc. | 69 | $87,081 |
| AbbVie | 71 | $80,561 |
| Boehringer Ingelheim International GmbH | 36 | $62,913 |
| Boehringer Ingelheim | 25 | $35,109 |
| E.r. Squibb & Sons, L.L.C. | 13 | $30,569 |
| Madrigal Pharmaceuticals | 17 | $27,894 |
| Ipsen Biopharmaceuticals, Inc | 15 | $27,251 |
| Merck | 13 | $22,182 |
| Novo Nordisk AS | 13 | $20,603 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $13,876 |
| F. Hoffmann-la Roche AG | 4 | $12,952 |
| Corcept Therapeutics | 6 | $8,842 |
| Siemens Medical Solutions USA, Inc. | 7 | $7,177 |
| Regeneron | 3 | $4,777 |
| Dova Pharmaceuticals | 5 | $4,218 |
| Vertex | 2 | $2,442 |
| Astrazeneca UK Limited | 2 | $2,283 |
| Theratechnologies Inc. | 1 | $2,000 |
| Boehringer Ingelheim Norway KS | 1 | $1,770 |
| AstraZeneca | 2 | $1,193 |
| Shionogi Inc | 2 | $756 |
| Novartis | 3 | $227 |
| Histosonics, Inc. | 1 | $140 |
| GSK | 1 | $114 |
| Sanofi Pasteur Inc. | 1 | $100 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$130,986
- OCALIVA$85,822
- Mavyret$79,647
- Wegovy$49,487
- Livdelzi$29,136
- REZDIFFRA$27,633
- IQIRVO$27,131
- Non-Covered Product$12,952
- DOPTELET$4,128
- MK-3655$1,500
- Ozempic$1,153
- Mulpleta$750
- ADVIA Immunoassay Reagents/Test Kit/Clinical Utilization$318
- FLUZONE HIGH-DOSE$100
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$100
How this compares
$776,285 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 11 | $32,849 |
| Ursodiol | 164 | $19,529 |
| Azathioprine | 49 | $1,641 |
| ConstuloseLactulose | 29 | $724 |
| Lactulose | 39 | $690 |
| Spironolactone | 45 | $304 |
| EnuloseLactulose | 13 | $246 |
| Furosemide | 37 | $168 |
| Tramadol Hcl | 46 | $76 |
| Carvedilol | 22 | $63 |
| Prednisone | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in San Antonio
- Charles RandallSan Antonio$749K
- Sandeep PatelSan Antonio$292K
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.